Mayne Pharma Group (MYX) investor relations material

Strategic focus and business overview

• Specializes in novel pharmaceuticals for dermatology and women's health, leveraging 40 years of oral drug delivery innovation.

• Operates globally with manufacturing in Australia and sales across the US, Canada, Europe, Asia, and Oceania.

• FY25 sales reached $408.1 million, with a market capitalization of $216.8 million and $86.7 million in cash and marketable securities as of March 2026.

• Top shareholders include Bruce Mathieson, Funicular Funds LP, Rubric Capital Management LP, and Trium Capital LLP.

Financial performance and segment highlights

• 3Q FY26 revenue was $85.2 million, up 1% year-on-year, with a gross margin of 63% (up from 59%).

• Underlying EBITDA improved 57% to -$1.4 million; adjusted operating cash flow rose 90% to $28.3 million.

• Women's Health segment saw US$26.4 million revenue (+7%), with strong growth in BIJUVA® and NEXTSTELLIS®.

• Dermatology revenue reached US$20.5 million (+1%), with gross profit up 34% and direct contribution up 55%.

• International segment revenue was $17.7 million (+19%), driven by NEXTSTELLIS® PBS approval and KADIAN® in Canada.

Margin expansion and branded product growth

• Branded products now represent 84% of net sales, up from 68% in FY24, driving gross margin expansion to 65%.

• Gross margin improved by 400 basis points year-on-year in 1H FY26.